Long-term changes in arterial structure and function and left ventricular geometry after enzyme replacement therapy in patients affected with Fabry disease

European Journal of Preventive Cardiology

Volumn 19, Issue 1, 2012, Pages 43-54

  Collin, Cédric ^a,b   Briet, Marie ^b   Tran, Thi Chien ^a,b   Beaussier, Hél�üne ^b   Benistan, Karelle ^a   Bensalah, Mourad ^c   Mousseaux, Elie ^c   Froissart, Marc ^c   Bozec, Erwan ^b   Laurent, Stéphane ^b   Boutouyrie, Pierre ^b   Germain, Dominique P ^a  

^a LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Enzyme replacement therapy; Fabry disease; large and medium sized arteries; left ventricular hypertrophy; ultrasonography

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA;

ADULT; ARTERIAL STIFFNESS; ARTERIAL WALL THICKNESS; ARTERY COMPLIANCE; ARTERY DIAMETER; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; COMMON CAROTID ARTERY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; ENZYME REPLACEMENT; FABRY DISEASE; FEMALE; FEMORAL ARTERY; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; LONG TERM CARE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PULSE PRESSURE; PULSE WAVE; RADIAL ARTERY; TONOMETRY; WALL STRESS; CARDIOVASCULAR RESPONSE; CAROTID ARTERY; CENTRAL PULSE PRESSURE; CLINICAL ARTICLE; DRUG EFFECT;

ADULT; ALPHA-GALACTOSIDASE; AORTA; BLOOD PRESSURE; CAROTID ARTERIES; CAROTID INTIMA-MEDIA THICKNESS; CASE-CONTROL STUDIES; COMPLIANCE; ENZYME REPLACEMENT THERAPY; FABRY DISEASE; FEMALE; FRANCE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; ISOENZYMES; LINEAR MODELS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING, CINE; MALE; MANOMETRY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; PULSATILE FLOW; RADIAL ARTERY; STROKE VOLUME; TIME FACTORS; TREATMENT OUTCOME; VASCULAR DISEASES; VENTRICULAR FUNCTION, LEFT; YOUNG ADULT;

EID: 84856894989     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1177/1741826710391118     Document Type: Article

References (47)

1. Brady RO, Gal AE, Bradley RM., et al. Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. N Engl J Med 1967; 276: 1163–1167.
2. Desnick R, Ioannou Y, Eng C. Alpha-galactosidase A deficiency: Fabry disease. The metabolic and molecular bases of inherited disease, 2001, 8th ed New York: McGraw Hill 3733–3774.
3. Wilcox WR, Oliveira JP, Hopkin RJ., et al. Females with Fabry disease frequently have major organ involvement: Lessons from the Fabry Registry. Mol Genet Metab 2008; 93: 112–128.
4. Barth P. Disorders of sphingolipid metabolism. Inborn Metab Dis 2000; 401–.412.
5. Eng CM, Guffon N, Wilcox WR., et al. Safety and efficacy of recombinant human alpha-galactosidase A–replacement therapy in Fabry's disease. N Engl J Med 2001; 345: 9–16.
6. Schiffmann R, Kopp JB, Austin HA., et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001; 285: 2743–2749.
7. Hoffmann B, Garcia de LA, Mehta A., et al. Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey). J Med Genet 2005; 42: 247–252.
8. Germain DP, Waldek S, Banikazemi M., et al. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 2007; 18: 1547–1557.
9. Mehta A, Beck M, Elliott P., et al. Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data. Lancet 2009; 374: 1986–1996.
10. Eng CM, Germain DP, Banikazemi M., et al. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med 2006; 8: 539–548.
11. Koskenvuo JW, Hartiala JJ, Nuutila P., et al. Twenty-four-month alpha-galactosidase A replacement therapy in Fabry disease has only minimal effects on symptoms and cardiovascular parameters. J Inherit Metab Dis 2008; 31: 432–441.
12. Weidemann F, Breunig F, Beer M., et al. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation 2003; 108: 1299–1301.
13. Mancia G, De BG, Dominiczak A., et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28: 1462–1536.
14. Boutouyrie P, Bussy C, Hayoz D., et al. Local pulse pressure and regression of arterial wall hypertrophy during long-term antihypertensive treatment. Circulation 2000; 101: 2601–2606.
15. Graham I, Atar D, Borch-Johnsen K., et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007; 14(Suppl 2): S1–S113.
16. Laurent S, Cockcroft J, Van Bortel L., et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006; 27: 2588–2605.
17. Asmar R, Benetos A, Topouchian J., et al. Assessment of arterial distensibility by automatic pulse wave velocity measurement. Validation and clinical application studies. Hypertension 1995; 26: 485–490.
18. Millasseau SC, Stewart AD, Patel SJ, Redwood SR, Chowienczyk PJ. Evaluation of carotid-femoral pulse wave velocity: influence of timing algorithm and heart rate. Hypertension 2005; 45: 222–226.
19. Tropeano AI, Boutouyrie P, Pannier B., et al. Brachial pressure-independent reduction in carotid stiffness after long-term angiotensin-converting enzyme inhibition in diabetic hypertensives. Hypertension 2006; 48: 80–86.
20. Girerd X, Giannattasio C, Moulin C., et al. Regression of radial artery wall hypertrophy and improvement of carotid artery compliance after long-term antihypertensive treatment in elderly patients. J Am Coll Cardiol 1998; 31: 1064–1073.
21. Hoeks AP, Brands PJ, Smeets FA, Reneman RS. Assessment of the distensibility of superficial arteries. Ultrasound Med Biol 1990; 16: 121–128.
22. Tardy Y, Meister JJ, Perret F, Brunner HR, Arditi M. Non-invasive estimate of the mechanical properties of peripheral arteries from ultrasonic and photoplethysmographic measurements. Clin Phys Physiol Meas 1991; 12: 39–54.
23. Bussy C, Boutouyrie P, Lacolley P, Challande P, Laurent S. Intrinsic stiffness of the carotid arterial wall material in essential hypertensives. Hypertension 2000; 35: 1049–1054.
24. Salton CJ, Chuang ML, O'Donnell CJ., et al. Gender differences and normal left ventricular anatomy in an adult population free of hypertension. A cardiovascular magnetic resonance study of the Framingham Heart Study Offspring cohort. J Am Coll Cardiol 2002; 39: 1055–1060.
25. Pouleur AC, le Polain de Waroux JB., et al. Assessment of left ventricular mass and volumes by three-dimensional echocardiography in patients with or without wall motion abnormalities: comparison against cine magnetic resonance imaging. Heart 2008; 94: 1050–1057.
26. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982; 38: 963–974.
27. Altarescu G, Moore DF, Pursley R., et al. Enhanced endothelium-dependent vasodilation in Fabry disease. Stroke 2001; 32: 1559–1562.
28. Barbey F, Brakch N, Linhart A., et al. Cardiac and vascular hypertrophy in Fabry disease: evidence for a new mechanism independent of blood pressure and glycosphingolipid deposition. Arterioscler Thromb Vasc Biol 2006; 26: 839–844.
29. Barbey F, Qanadli SD, Juli C., et al. Aortic remodelling in Fabry disease. Eur Heart J 2010; 31: 347–353.
30. Moore DF, Ye F, Brennan ML., et al. Ascorbate decreases Fabry cerebral hyperperfusion suggesting a reactive oxygen species abnormality: an arterial spin tagging study. J Magn Reson Imaging 2004; 20: 674–683.
31. Moore DF, Gelderman MP, Ferreira PA., et al. Genomic abnormalities of the murine model of Fabry disease after disease-related perturbation, a systems biology approach. Proc Natl Acad Sci U S A 2007; 104: 8065–8070.
32. Faraci FM, Didion SP. Vascular protection: superoxide dismutase isoforms in the vessel wall. Arterioscler Thromb Vasc Biol 2004; 24: 1367–1373.
33. Boutouyrie P, Laurent S, Laloux B., et al. Arterial remodelling in Fabry disease. Acta Paediatr Suppl 2002; 91: 62–66.
34. Vedder AC, Linthorst GE, van Breemen MJ., et al. The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels. J Inherit Metab Dis 2007; 30: 68–78.
35. Elleder M, Bradova V, Smid F., et al. Cardiocyte storage and hypertrophy as a sole manifestation of Fabry's disease. Report on a case simulating hypertrophic non-obstructive cardiomyopathy. Virchows Arch A Pathol Anat Histopathol 1990; 417: 449–455.
36. von Scheidt W, Eng CM, Fitzmaurice TF., et al. An atypical variant of Fabry's disease with manifestations confined to the myocardium. N Engl J Med 1991; 324: 395–399.
37. Kolter T, Sandhoff K. Recent advances in the biochemistry of sphingolipidoses. Brain Pathol 1998; 8: 79–100.
38. Brakch N, Dormond O, Bekri S., et al. Evidence for a role of sphingosine-1 phosphate in cardiovascular remodelling in Fabry disease. Eur Heart J 2010; 31: 67–76.
39. Wilcox WR, Banikazemi M, Guffon N., et al. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 2004; 75: 65–74.
40. Boutouyrie P, Bussy C, Lacolley P., et al. Association between local pulse pressure, mean blood pressure, and large-artery remodeling. Circulation 1999; 100: 1387–1393.
41. MacDermot J, MacDermot KD. Neuropathic pain in Anderson-Fabry disease: pathology and therapeutic options. Eur J Pharmacol 2001; 429: 121–125.
42. Beer M, Weidemann F, Breunig F., et al. Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy. Am J Cardiol 2006; 97: 1515–1518.
43. Hughes DA, Elliott PM, Shah J., et al. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart 2008; 94: 153–158.
44. Desnick RJ, Blieden LC, Sharp HL, Hofschire PJ, Moller JH. Cardiac valvular anomalies in Fabry disease. Clinical, morphologic, and biochemical studies. Circulation 1976; 54: 818–825.
45. Girerd X, Laurent S, Pannier B, Asmar R, Safar M. Arterial distensibility and left ventricular hypertrophy in patients with sustained essential hypertension. Am Heart J 1991; 122: 1210–1214.
46. Ross AJ, Yang Z, Berr SS., et al. Serial MRI evaluation of cardiac structure and function in mice after reperfused myocardial infarction. Magn Reson Med 2002; 47: 1158–1168.
47. Germain DP., et al. Fabry disease. Orphanet J Rare Dis 2010; 30.